Cited by 250Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis MechanismsPlatelet Disorders and Treatments

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice

Edwards, Michael H., Pierangeli, Silvia, Liu, XiaoWei, Barker, John H., Anderson, Gary, Harris, E. Nigel·1997·Circulation

DOI 10.1161/01.cir.96.12.4380

Open this paper in CoChat — free account

Abstract

Background Previous studies have demonstrated that human monoclonal and polyclonal anticardiolipin antibodies have thrombogenic properties in vivo. Using such a model in which these antibodies have been shown to increase both the size of an induced thrombus and the duration of time in which such a clot lasts, we investigated whether hydroxychloroquine alters the dynamics of such thrombus formation. Methods and Results Three groups of nine mice were injected with purified immunoglobulin G (IgG) from a patient with the antiphospholipid syndrome (IgG-APS) and then fed with hydroxychloroquine at various doses (100, 6, and 3 mg/kg body wt). Three control groups of mice were also studied, including mice injected with IgG-APS and then fed with placebo, as well as two other groups injected with IgG from normal human serum and fed either hydroxychloroquine or placebo. A standardized thrombogenic injury was subsequently induced in the femoral vein of each mouse and the area (size) of thrombus measured as well as the total period of time that thrombus was present. Mice treated with hydroxychloroquine and IgG-APS showed significantly smaller thrombi that persisted for a shorter period of time compared with animals treated with IgG-APS and placebo. Conclusions Hydroxychloroquine significantly diminished both thrombus size and total time of thrombus formation in mice previously injected with IgG-APS.

Integrity signals

Registry

Crossref · 10.1161/01.cir.96.12.4380

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Handbook of Experimental Immunology.
Denman, A. (1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-6-1376_1 · Cited by 2,414
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700
SYNDROME OF THE BLACK SWAN
Harris, E. N. (1987) · Lara D. Veeken · doi:10.1093/rheumatology/26.5.324 · Cited by 404
Self-citation
Phospholipase A2 activity specific for phosphatidic acid. A possible mechanism for the production of arachidonic acid in platelets.
Billah, M. M., Lapetina, E. G., & Cuatrecasas, P. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69214-8 · Cited by 369
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment.
Derksen, R. H. W. M., de Groot, P. G., Kater, L., & Nieuwenhuis, H. K. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.9.689 · Cited by 240
Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes.
Khamashta, M. A., Harris, E. N., Gharavi, A. E., Derue, G., Gil, A., Vázquez, J. J., & Hughes, G. R. V. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.10.849 · Cited by 226
Self-citation
Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome
Pierangeli, S. S., Liu, X. W., Barker, J. H., Anderson, G., & Harris, E. N. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649940 · Cited by 223
Self-citation
ANTIPHOSPHOLIPID ANTIBODIES
Harris, E. N. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb02530.x · Cited by 222
Self-citation
Pulmonary Embolism and its Prophylaxis Following the Charnley Total Hip Replacement
JOHNSON, R., Green, J. R., & Charnley, J. (1977) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-197709000-00015 · Cited by 179

Show all 30 references

Research works printed but not linked: 4

Knisely M, Bloch E. Microscopic observations of intravascular agglutination of red cells and consequent sludging of blood in human diseases. Anat Rec.. 1942;82:426.
10.1161/circ.94.7.1746 · DOI
Cecchi E, Ferraris D. Desludging action of hydroxychloroquine in rheumatoid arthritis. Acta Med Scand.. 1962;8:214-221.
Bird H, Harkness J, Wright V. Some rheological properties of blood during antirheumatoid therapy. Pharmatherapeutica.. 1981;3:36-39.

Sorted by citations

Items 101–200 of 249

Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial
Hartman, O., Kovanen, P. T., Lehtonen, J. Y. A., Eklund, K. K., & Sinisalo, J. P. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw035 · Cited by 33
Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease
Ünlü, O., & Erkan, D. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-102529 · Cited by 33
Treatment of antiphospholipid syndrome
Radin, M., Cecchi, I., Rubini, E., Foddai, S. G., Barinotti, A., Menegatti, E., Roccatello, D., & Sciascia, S. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108597 · Cited by 32
New targeted therapies for treatment of thrombosis in antiphospholipid syndrome
Pierangeli, S. S., Vega-Ostertag, M. E., & González, E. B. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000506 · Cited by 31
Self-citation
Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus
Pietté, J. C., Sbaï, A., & Francès, C. (2002) · Lupus · doi:10.1191/0961203302lu180ed · Cited by 31
Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review
Hooper, A., Bacal, V., & Bedaiwy, M. A. (2023) · American Journal of Reproductive Immunology · doi:10.1111/aji.13761 · Cited by 28
Prevention and management of co-morbidities in SLE
Bichile, T., & Petri, M. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.03.009 · Cited by 28
Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update
Pal, A., Pawar, A. T., Goswami, K., Sharma, P., & Prasad, R. (2020) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-020-00900-x · Cited by 27
Anti‐phospholipid antibodies and reproductive failures
Beltagy, A., Trespìdi, L., Gerosa, M., Ossola, M. W., Meroni, P. L., & Chighizola, C. B. (2020) · American Journal of Reproductive Immunology · doi:10.1111/aji.13258 · Cited by 28
Thrombosis and antiphospholipid antibody syndrome during acute Q fever
Million, M., Bardin, N., Bessis, S., Nouiakh, N., Douliery, C., Edouard, S., Angelakis, E., Bosseray, A., Épaulard, O., Branger, S., et al. (2017) · Medicine · doi:10.1097/md.0000000000007578 · Cited by 26
Antiphospholipid syndrome
Erkan, D., & Lockshin, M. D. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000218943.89365.13 · Cited by 26
Atomic force microscopy: High resolution dynamic imaging of cellular and molecular structure in health and disease
Taatjes, D. J., Quinn, A. S., Rand, J. H., & Jena, B. P. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24363 · Cited by 23
Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome
Urbanski, G., Caillon, A., Poli, C., Kauffenstein, G., Bégorre, M.-A., Loufrani, L., Henrion, D., & Belizna, C. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206814 · Cited by 23
Targeted therapy in antiphospholipid syndrome
Sciascia, S., Khamashta, M. A., & D’Cruz, D. P. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000051 · Cited by 23
Immunotherapy in antiphospholipid syndrome
López-Pedrera, C., Aguirre, M. A., Ruiz‐Limón, P., Pérez‐Sánchez, C., Jiménez, Y., Barbarroja, N., & Cuadrado, M. J. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.06.006 · Cited by 23
Induction and treatment of the antiphospholipid syndrome – lessons from animal models
Shoenfeld, Y., Blank, M., & Sherer, Y. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00866.x · Cited by 23
The treatment of antiphospholipid syndrome: A harmonic contrast
Ruiz‐Irastorza, G., & Khamashta, M. A. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.10.003 · Cited by 23
Antiphospholipid syndrome: an update for clinicians and scientists
Vreede, A. P., Bockenstedt, P. L., & Knight, J. S. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000410 · Cited by 22
Difficult Clinical Situations in the Antiphospholipid Syndrome
Rosa, R. F., Lopes, M. R. U., Zeinad, A. K., D’Amico, É. A., & ANDRADE, D. C. O. D. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0502-7 · Cited by 22
Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?
Meroni, P. L. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.07.003 · Cited by 22
Recent advances in the antiphospholipid antibody syndrome
Chaturvedi, S., & McCrae, K. R. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000067 · Cited by 22
Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain
Ichihara, K., Aizawa, N., Akiyama, Y., Kamei, J., Masumori, N., Andersson, K., Homma, Y., & Igawa, Y. (2017) · Pain · doi:10.1097/j.pain.0000000000000947 · Cited by 21
Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer
Niemann, B. R., Puleo, A., Stout, C., Markel, J., & Boone, B. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122551 · Cited by 19
Systemic lupus erythematosus: modern strategies for management – a moving target
King, J. K., & Hahn, B. H. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.09.002 · Cited by 18
Hydroxychloroquine dans le traitement du lupus : le renouveau
Costedoat-Chalumeau, N., Leroux, G., Amoura, Z., & Pietté, J. C. (2007) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.05.031 · Cited by 18
Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19
Scheim, D. E., Vottero, P., Santin, A. D., & Hirsh, A. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317039 · Cited by 18
Management of antiphospholipid syndrome
Papa, N. D., & Vaso, N. (2010) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10365969 · Cited by 15
Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus
Peng-Cheng, L., Meng-Na, L., Li, J., Shu-Jiao, Y., & Wu, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30393 · Cited by 14
Management of the antiphospholipid syndrome
DeMarco, P., Singh, I., & Weinstein, A. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0051-1 · Cited by 14
Hydroxychloroquine : une nouvelle approche thérapeutique des manifestations thrombotiques du syndrome des antiphospholipides
Szymezak, J., Ankri, A., Fischer, A., & Darnige, L. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2010.08.018 · Cited by 14
Le syndrome des antiphospholipides
Arvieux, J., & HACHULLA, E. (2002) · Annales de Cardiologie et d Angéiologie · doi:10.1016/s0003-3928(02)00087-2 · Cited by 14
Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE
Toubi, E., Kessel, A., Rosner, I., Rozenbaum, M., Lorber, M., Paran, D., Sabo, E., & Golan, T. D. (2003) · Lupus · doi:10.1191/0961203303lu319oa · Cited by 14
The additional use of hydroxychloroquine can improve the live birth rate in pregnant women with persistent positive antiphospholipid antibodies: A systematic review and meta-analysis
Tian, Y., Xu, J., Chen, D., Yang, C., & Peng, B. (2021) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2021.102121 · Cited by 13
Antipalúdicos: actualización de su uso en enfermedades reumáticas
Palop, M. J. (2006) · Reumatología Clínica · doi:10.1016/s1699-258x(06)73045-5 · Cited by 13
Treatment of thrombotic antiphospholipid syndrome in adults and children
Madison, J. A., Duarte‐García, A., Zuo, Y., & Knight, J. S. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000702 · Cited by 12
Osteoarticular Manifestations of Antiphospholipid Syndrome
Tektonidou, M. G., & Moutsopoulos, H. Μ. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.003 · Cited by 12
Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study
Broder, A. R., Mowrey, W. B., Kim, M., Murakhovskaya, I., Billett, H. H., Neugarten, J., Costenbader, K. H., & Putterman, C. (2015) · Rheumatology · doi:10.1093/rheumatology/kev423 · Cited by 11
Current management of antiphospholipid syndrome-related thrombosis
Puente, D., Pombo, G., & Forastiero, R. R. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.112 · Cited by 11
A novel antiphospholipid antibody agent?
Hunt, B. J. (2010) · Blood · doi:10.1182/blood-2009-12-258889 · Cited by 11
Antiphospholipid Syndrome
Wysokinska, E. M., & Ortel, T. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00020-0 · Cited by 11
Evidence-based management of thrombosis in the antiphospholipid antibody syndrome
Petri, M. (2003) · Current Rheumatology Reports · doi:10.1007/s11926-003-0023-7 · Cited by 11
The Contribution of Experimental Models to our Understanding of Etiology, Pathogenesis and Novel Therapies in the Antiphospholipid Syndrome
Blank, M., Krause, I., & Shoenfeld, Y. (2000) · Springer eBooks · doi:10.1007/978-1-4471-3666-8_38 · Cited by 11
Hydroxychloroquine inhibits hemolysis-induced arterial thrombosis ex vivo and improves lung perfusion in hemin-treated mice
Bourne, J. H., Perrella, G., El-Awaisi, J., Terry, L. V., Tinkova, V. V., Hogg, R. L., Gant, P., Grygielska, B., Kalia, N., Kavanagh, D. P. J., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.04.008 · Cited by 10
Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome
Liu, M., Li, G., Song, X., Fan, Y., & Li, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-35955-2 · Cited by 10
The ABCs of antiphospholipid syndrome
Dinçer, A. B. K., & Erkan, D. (2023) · Archives of Rheumatology · doi:10.46497/archrheumatol.2023.41875 · Cited by 11
Current status and future prospects for the treatment of antiphospholipid syndrome
Marzooqi, A. A., Leone, A., Saleh, J. A., & Khamashta, M. A. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1178573 · Cited by 10
How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive
Giles, I., & Rahman, A. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.01.009 · Cited by 11
Antimalariamittel
Fischer-Betz, R., & Schneider, M. (2008) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-008-0412-4 · Cited by 10
Systemic lupus erythematosus in the elderly: antimalarials in disease remission
Shinjo, S. K. (2009) · Rheumatology International · doi:10.1007/s00296-009-0907-6 · Cited by 10
Lipid-binding antiphospholipid antibodies: significance for pathophysiology and diagnosis of the antiphospholipid syndrome
Müller-Calleja, N., Ruf, W., & Lackner, K. J. (2024) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2024.2305121 · Cited by 11
Anti-malarials: Are There Benefits Beyond Mild Disease?
Sharma, T. S., Joyce, E., & Wasko, M. C. (2016) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-016-0036-9 · Cited by 9
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
Devaux, C. A., Camoin‐Jau, L., Mège, J., & Raoult, D. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.12.010 · Cited by 9
Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in rats
Li, X., Liao, X., Yan, X., Yuan, Y., Yuan, Z., Liu, R., Xu, Z., Wang, Q., Xu, Q., Li, R., et al. (2022) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2022.105114 · Cited by 9
Grossesse et anticorps antiphospholipides
Guern, V. L., & Goffinet, F. (2008) · La Presse Médicale · doi:10.1016/j.lpm.2008.08.001 · Cited by 9
Duration of Anticoagulation Treatment for Thrombosis in APS: Is It Ever Safe to Stop?
Punnialingam, S., & Khamashta, M. A. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0318-2 · Cited by 9
Antimalarials in systemic lupus erythematosus: benefits beyond disease activity
Andrade, R. M., & Alarcón, G. S. (2006) · Future Rheumatology · doi:10.2217/17460816.1.2.225 · Cited by 9
Antiphospholipid antibody syndrome: the problems and the promise
Piette, W. W. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03590.x · Cited by 9
Le risque cardiovasculaire au cours du lupus systémique
Arnaud, L., Mathian, A., Bruckert, É., & Amoura, Z. (2014) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2014.07.005 · Cited by 8
Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses
Scheim, D. E., Parry, P. I., Rabbolini, D. J., Aldous, C. M., Yagisawa, M., Clancy, R. L., Borody, T. J., & Hoy, W. E. (2024) · Viruses · doi:10.3390/v16040647 · Cited by 8
Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety
Qushmaq, N. A., & Al-Emadi, S. A. (2014) · ISRN Rheumatology · doi:10.1155/2014/348726 · Cited by 8
Antipaludéens de synthèse
Fardet, L., & Revuz, J. E. (2005) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(05)79414-x · Cited by 8
New and upcoming treatments in antiphospholipid syndrome: A comprehensive review
Signorelli, F., Balbi, G. G. M., Domingues, V., & Levy, R. A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.012 · Cited by 8
Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases
Mayer-Pickel, K. I., Stern, C., Cervar-Zivkovic, M., Schöll, W., & Moertl, M. G. (2020) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2020.103101 · Cited by 8
Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies
Cannella, A. C., & O’Dell, J. R. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3285-4.10056-7 · Cited by 7
The effect of hydroxychloroquine on platelet activation in model experiments
Schreiber, K. I., Sciascia, S., Wehrmann, F., Weiß, C., Leipe, J., Krämer, B. K., & Stach, K. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02325-y · Cited by 7
Antiphospholipid antibody syndrome
Cucurull, E., Gharavi, A. E., Menon, Y., & Wilson, W. A. (2003) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-003-0021-0 · Cited by 7
Antiphospholipid syndrome: long-time research on pathogenic mechanisms has finally lead to new therapeutic strategies
Cervera, R., & Espinosa, G. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.530900 · Cited by 7
Parvovirus B19 Infection Is Associated with the Formation of Neutrophil Extracellular Traps and Thrombosis: A Possible Linkage of the VP1 Unique Region
Tzang, B., Chin, H.-Y., Tzang, C.-C., Chuang, P.-H., Chen, D., & Hsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189917 · Cited by 6
A new trick for an ancient drug: quinine dissociates antiphospholipid immune complexes
Bezati, E., Wu, X.-X., Quinn, A., Taatjes, D. J., & Rand, J. H. (2014) · Lupus · doi:10.1177/0961203314547792 · Cited by 7
Traditional DMARDs
Cannella, A. C., & O’Dell, J. R. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00061-x · Cited by 6
Síndrome antifosfolipídico en el siglo xxi
Ruiz‐Irastorza, G., Martínez-Berriotxoa, A., & Egurbide, M. V. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2008.10.046 · Cited by 6
Reimagining the antiphospholipid syndrome, an enigmatic thrombophilic disorder, through the looking glass of microscopic imaging
Rand, J. H., & Taatjes, D. J. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1709-2 · Cited by 5
Traditional DMARDs
Cannella, A. C., & O’Dell, J. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00061-9 · Cited by 5
Dermatologic Manifestations in the Antiphospholipid Syndrome
Francès, C., & Piette, J. C. (2002) · Elsevier eBooks · doi:10.1016/b978-044450987-1/50025-5 · Cited by 5
Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis
Willis, R., Cohen, H., Giles, I., Knight, J. S., Krilis, S. A., Rahman, A., & de Groot, P. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_5 · Cited by 5
Management of Thrombosis in the Antiphospholipid Syndrome
Khamashta, M. A. (2000) · Springer eBooks · doi:10.1007/978-1-4471-3666-8_39 · Cited by 5
Hydroxychloroquine sulfate for IgA nephropathy: mechanisms and therapeutic potential in improving proteinuria and alleviating disease progression - a literature review
Yilei, L., Du, Y., Yaxuan, F., Liu, C., Tingzhu, C., Li, J., Rao, X.-R., & Guo, C. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04262-5 · Cited by 4
Treatment of Autoimmune Disease: Established Therapies
Tiong, B. K., Hahn, B. H., & Aung, T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00071-3 · Cited by 4
The Pathophysiology of Antiphospholipid Syndrome
Sada, P. R., Cohen, H., & Isenberg, D. A. (2015) · The Open Urology & Nephrology Journal · doi:10.2174/1874303x01508010002 · Cited by 4
Wide Applications of Chloroquine Other Than Antimalarial
Alani, B. G., Alwash, A. H., & Ibrahim, I. T. (2020) · Pharmacology & Pharmacy · doi:10.4236/pp.2020.1110022 · Cited by 4
HEMATOLOGY: COAGULATION PROBLEMS
Shapiro, S. S., & Spurgeon, S. E. F. (2004) · Elsevier eBooks · doi:10.1016/b978-012433901-9/50045-4 · Cited by 4
Antiphospholipid syndrome: why and how should we make the diagnosis?
Sibilia, J. (2003) · Joint Bone Spine · doi:10.1016/s1297-319x(03)00014-9 · Cited by 4
Faut-il doser l'hydroxychloroquine chez les patients lupiques ?
Costedoat-Chalumeau, N., Amoura, Z., Hulot, J., Lechat, P. P., & Pietté, J. C. (2006) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2006.05.002 · Cited by 4
Traitement des complications thrombotiques du syndrome des anticorps antiphospholipides : éclairages des essais thérapeutiques récents et zones d’ombre
Wahl, D. G., Perret‐Guillaume, C., & Pietté, J. C. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2008.05.013 · Cited by 4
Treatment of antiphospholipid antibody syndrome
Mehdi, A. A., Uthman, I. W., & Khamashta, M. A. (2010) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.10.8 · Cited by 4
Neuropsychiatric SLE: From Immune Mechanisms to Clinical Management
Zhang, E., & Jørgensen, T. N. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82183 · Cited by 4
The Antiphospholipid Syndrome: Clinical Presentation, Diagnosis, and Patient Management
Rand, J. H., Levin, M. B., & Alving, B. M. (2007) · Elsevier eBooks · doi:10.1016/b978-141602401-9.10019-7 · Cited by 4
Management of Thrombosis in Antiphospholipid Syndrome
Khamashta, M. A., & Ruiz‐Irastorza, G. (2006) · Springer eBooks · doi:10.1007/1-84628-009-5_43 · Cited by 4
Platelet Activation and Autoimmunity: Mechanisms Linking Hemostasis and Cardiovascular Risk in Rheumatologic Disease
Ni, R., Barrett, T. J., & Garshick, M. S. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047468 · Cited by 3
Antiphospholipid Syndrome: An Important Differential Diagnosis for Culture-negative Endocarditis
Wang, L. W., Noël, B., Descloux, É., & Baron, D. W. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.11.010 · Cited by 3
Cardiovascular Involvement in Systemic Lupus Erythematosus
Abdulaziz, S., Al-Ghamdi, Y., Samannodi, M. S., & Shabrawishi, M. (2012) · InTech eBooks · doi:10.5772/37351 · Cited by 3
Metabolic syndrome in inflammatory rheumatic diseases
Malesci, D., Valentini, G., & MONTAGNA, G. L. (2011) · Reumatismo · doi:10.4081/reumatismo.2006.169 · Cited by 3
Le risque cardiovasculaire accru du lupus : données physiopathologiques et thérapeutiques
Boffa, J., Rougier, J., Noël, N., & Ronco, P. M. (2009) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2009.06.009 · Cited by 3
Antimalarials and SLE
Costedoat-Chalumeau, N., Leroux, G., Pietté, J. C., & Amoura, Z. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10057-9 · Cited by 3
Desirable and Adverse Effects of Antiinflammatory Agents on the Heart
Imazio, M., Maestroni, S., Valenti, A., Ramoni, V. L., & Brucato, A. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803267-1.00025-9 · Cited by 3
Osteoarticular Manifestations of Antiphospholipid Syndrome
Tektonidou, M. G., & Moutsopoulos, H. Μ. (2006) · Springer eBooks · doi:10.1007/1-84628-009-5_12 · Cited by 3
Antiphospholipid Syndrome
Siddique, F., Patel, D. P., & Roberts, W. N. (2016) · Compendium of Inflammatory Diseases · doi:10.1007/978-3-7643-8550-7_161 · Cited by 3
Management of the Difficult Aspects of the Antiphospholipid Syndrome
Erkan, D., Sammaritano, L. R., & Lockshin, M. D. (2002) · Elsevier eBooks · doi:10.1016/b978-044450987-1/50036-x · Cited by 3
Tratamiento del síndrome antifosfolipídico, ¿a quién, cuándo y cuánto tiempo?
Castañeda, M. C. A. (2005) · Reumatología Clínica · doi:10.1016/s1699-258x(05)72773-x · Cited by 2
Management of the antiphospholipid syndrome: new approaches
Seif, A. M., Hwang, Y. G., & Pierangeli, S. S. (2009) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.09.43 · Cited by 2
Self-citation

Authors: Edwards, M. H., Pierangeli, S., Liu, X., Barker, J. H., Anderson, G., & Harris, E. N.
Affiliations: University of Louisville (US)
ORCID: Liu, XiaoWei
Barker, John H.
Anderson, Gary
Harris, E. Nigel
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1997-12-16
Volume: 96
Issue: 12
Pages: 4380-4384
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.96.12.4380
OpenAlex: W2001976130
Cited by: 250
References: 30
Citations by year: 2026: 3 · 2025: 1 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 6 · 2020: 17 · 2019: 9 · 2018: 7 · 2017: 13 · 2016: 14 · 2015: 10 · 2014: 16 · 2013: 11 · 2012: 10
FWCI: 2.01
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords: hydroxychloroquine, antiphospholipid syndrome, anticardiolipin antibodies, antiphospholipid antibodies, thrombosis, thrombus size, thrombogenicity, IgG, thromboprophylaxis
MeSH terms: Animals, Dose-Response Relationship, Drug, Humans, Hydroxychloroquine, Immunoglobulin G, Male, Mice, Inbred Strains, Reference Values, Thrombosis, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks